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90 Poster Session Ian easily available source of stemcells for patients everywhere. The
increasing worldwide repository of CB units is improving the chan-
ces of finding a matched unit for more patients. We present our ex-
perience with UCBT as a single source of stem cells for unrelated
transplantation in these patients.
CBSearchMethods:Matched unrelated CB searches were done
for 67 pediatric pts (0–16 yrs) with malignant (MD, n 5 44) and
nonmalignant (NMD, n 5 23) disease from 1995 to 2007 in the
NY Blood Center and Netcord. The probability of finding a 5/6
CB unit with. 3.0  10 7/kg (optimal match) was calculated com-
paring the period 1995–2001 vs 2002–07.Transplant Patients and
Methods: 32 pts. (MD5 19, NMD5 13) receivedUCBT between
1996 and 2007. 12 pts with MD were standard risk (SR) for trans-
plantation (ALL CR1–2, ANLL CR1, CML CP, MDS RAEB/
RAEBt).1 pt received a 3/6, 18 a 4/6, 13 pts a 5/6 graft. Median
cell dose was 4.3  107/kg (2.6–16.3). 3 pts received a double graft.
Conditioning regimens were adapted to diagnosis. NMD received
BuCyATG. 17 MD pts and 1 NMD pt received TBI. GvHD pro-
phylaxis was CsA plus prednisone (n 5 26), mtx (n 5 2) or MMF
(n 5 4). Engraftment and EFS analysis was done for the entire
group of transplanted pts and the MDSR plus NMD subset (n 5
25). HLA match (5/6 vs others), cell dose (\4.0 vs .4.0 10 7/kg)
and year of UCBT (96–01 vs 01–07) were compared for engraft-
ment and survival in this subset. Results: An optimal matched CB
unit was found for 6/41 pts (14%) in the 1995–2001 period vs 17/
26 (65%, p . 0.001) in the 2001–2007 period. 19 transplanted pts
(61%) engrafted. TRM was 25%, MD relapse 22%. EFS was
31% with median f/u of 21 months. Subset analysis of MDSR
plus NMD pts showed engraftment of 70% and 3 yr EFS of 36%.
In this group the only prognostic factor for survival wasHLAmatch
(5/6 vs 3/6 and 4/6:Hazard Ratio 14, p\0.001).Conclusion:CB is
a good alternative for unrelated stem cell transplantation in chil-
dren. HLA matching appears to be the most important prognostic
factor given a cell dose . 3.0  10 7/kg. Increasing availability of
optimal matched CB units worldwide will make this approach fea-
sible for more patients.243
AUTOLOGOUS STEM CELL TRANSPLANTATION IN CHILDREN WITH RE-
FRACTORY OR RELAPSED HODGKIN DISEASE IN COLOMBIA
Linares, A., Abello, V., Rosales, C., Pedraza, E., Esguerra, H.J.,
Rosales, M.L. Clınica de Marly, Bogota, Colombia.
Here we report a retrospective analysis performed to evaluate the
results of autologous hematopoietic stem cell transplantation in pe-
diatric patients withHodgkinDisease (HD) in a single center in Bo-
gota, Colombia.
Nineteen patients with relapsed or refractory HD underwent au-
tologous stem cell transplantation between 1998 and 2006. 8 fe-
male/11 male, with mean age of 10.9 years (7–14). At diagnosis
patients were staged: I and IIA 10, IIB 1, IIIA 1, IIIB 4 and stage
IV 6. The response to first line therapy was: 8 patients had failure
to induction, and 6 early relapse (before 12 months). At transplan-
tation: 10 patients were in 2nd complete remission, 2 in 3th com-
plete remission and 7 were in partial remission. The conditioning
regimenwas BEAM in 14 patients and other protocols with carmus-
tine, etoposide and cyclophosphamide or melphalan in 5 patients.
With a mean 26 months of follow-up, (8–66), the 5 year OS was
73.3% and EFS of 51.9%. 8/19 patients (42%) relapsed between 3
and 48 months after transplantation, the main cause of death was
progressive disease. One patient died before day1100 with a severe
fungal infection.
This study group is too small to establish prognostic factors for
relapse after transplantation, although is important for countries
with limited resources to have data about local results. The OS
and EFS in this group are similar to results in developed countries.
Near 50% of patients with refractory or relapsed HD can be suc-
cessfully treated with high dose chemotherapy and autologous
stem cell rescue. It’s important to have a longer follow up on these
patients so we can perform analysis on prognostic factors for relapse
and survival.SOLID TUMORS
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TREATMENT OF EPSTEIN BARR VIRUS POSITIVE NASOPHARYNGEAL
CARCINOMA WITH ADOPTIVELY TRANSFERRED CYTOTOXIC T LYM-
PHOCYTES
Louis, C.U., Straathof, K., Gerken, C., Cooper-Havlik, D., Torrano, V.,
Lopez, T., Bollard, C.M., Gresik, M.V., Weiss, H., Gee, A.,
Brenner, M.K., Rooney, C.M., Heslop, H.E., Gottschalk, S. Baylor Col-
lege of Medicine, The Methodist Hospital, Texas Children’s Hospital,
Houston, TX.
Background: The strong association of nasopharyngeal carci-
noma (NPC) with Epstein-Barr virus (EBV) makes adoptive immu-
notherapy with EBV-specific cytotoxic T cells (EBV-CTL) an
attractive therapeutic option. We have evaluated the safety and ef-
ficacy of EBV-specific CTL (EBV-CTL) in two Phase I clinical tri-
als. In the first trial, EBV-CTL were given alone and in the second
trial, we aimed to enhance in vivo expansion of EBV-CTL by lym-
phodepleting patients prior to CTL infusion. For lymphodepletion
we used CD45 monoclonal antibodies (MAbs) that unlike chemo-
therapy or radiation do not result in nonspecific destruction of
the resident immune system. Study Design:The primary objective
of these Phase I clinical trials was to determine the safety of escalat-
ing doses of EBV-CTL with or without lymphodepletion in EBV-
positive NPC patients. The secondary objective was to determine
the expansion, persistence and anti-tumor effects of infused EBV-
CTL. Results: Thirty two patients with advanced-stage NPC re-
ceived autologous EBV-CTL. Patients received a median of 2
(range 1–6) doses of CTL at 2  107–2 108 cells/m2 per infusion.
CTL administration was well tolerated except for transient swelling
at known disease sites in 4 patients. Prior to CTL infusion, 8 pa-
tients were in remission, 22 had active disease, and 2 had abnormal
imaging studies of unknown significance. Seven of 8 patients in re-
mission prior to CTL infusion remain in remission 6–64 months
post CTL. For the remaining 24 patients, the best overall response
rate was 50% with 6 complete responses (CR/CRu), 2 partial re-
sponses, and 4 with stable disease during a median follow-up of 9
months (95%CI 2–16months). Of the 6 with a CR: 4 have been sus-
tained for 2–4 years, and 2 relapsed more than 2 years post CTL.
Ten patients with active disease received CD45 MAbs prior to
EBV-CTL and 8 were evaluable for immune reconstitution analy-
sis. Infusion of CD45 MAbs resulted in transient lymphopenia (re-
solved within 7 days), increased serum IL-15 levels in 6 patients, and
significant expansion of EBV-CTL within 8 weeks post-infusion in
3 patients. Conclusion: Treatment of EBV-positive NPC with
EBV-CTL appears safe and can be associated with significant
anti-tumor activity. Lymphodepletion with CD45 MAbs prior to
CTL infusion is also safe and results in expansion of adoptively
transferred CTL in a subset of patients. These encouraging results
warrant further exploration of EBV-targeted immunotherapies for
NPC.245
REGRESSION OF EXPERIMENTAL OSTEOSARCOMA AND EWING’S SAR-
COMA FOLLOWING TRANSFER OF HER2-REDIRECTED T CELLS
Ahmed, N.1, Salsman, V.S.1, Louis, C.L.1, Dishop, M.1, Weiss, H.L.1,
Kleinerman, E.S.2, Rooney, C.M.1, Heslop, H.E.1, Gottschalk, S.1,3.
1Baylor College of Medicine, Houston, TX; 2University of Texas, Hous-
ton, TX; 3Baylor College of Medicine, Houston, TX.
Background: New therapies are needed for osteosarcoma (OS)
and Ewing’s sarcoma (EWS) since the prognosis for patients with
metastatic and/or recurrent disease has not improved over the last
two decades despite aggressive multimodal therapies. For immuno-
therapies,HER2 is an attractive target since it is expressed in 40%
of OS and up to 25% of EWS.While the use of HER2 monoclonal
antibodies has been limited by low levels of HER2 expression on
sarcoma cells, we show here that T cells expressing HER2-specific
chimeric antigen receptors (CARs) have potent anti-sarcoma activ-
ity in animal models. Methods: Mitogen-activated T cells were
transduced with a retroviral vector encoding a HER2-specific
CAR with a CD28.z-signaling endodomain (HER2-T cells). We
